Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Andrew Acheampong"'
Autor:
Allan Weber, Jinsong Ni, Kah-Hiing John Ling, Andrew Acheampong, Diane D-S. Tang-Liu, Robert Burk, Benjamin F. Cravatt, David Woodward
Publikováno v:
Journal of Lipid Research, Vol 45, Iss 4, Pp 757-763 (2004)
We investigated the formation of PGF2α 1-ethanolamide, PGE2 1-ethanolamide, and PGD2 1-ethanolamide (prostamides F2α, E2, and D2, respectively) in liver, lung, kidney, and small intestine after a single intravenous bolus administration of 50 mg/kg
Externí odkaz:
https://doaj.org/article/dd23b20e2bfb4e229670a1694a0b90e7
Autor:
Takeo Sakuma, Andrew Acheampong, Devin F. Welty, Carmai Seto, Gabriella Szekely-Klepser, Jinsong Ni, Robert Ellis, Hui Ouyang, Josh Rowe
Publikováno v:
Bioanalysis. 2:407-419
Background: The objective of this study was to evaluate the sensitivity requirement for LC–MS/MS as an analytical tool to characterize metabolites in plasma and urine at microdoses in rats and to investigate proportionality of metabolite exposure f
Autor:
Andrew Acheampong, Devin F. Welty, Carmai Seto, Jinsong Ni, Takeo Sakuma, Lisa Borbridge, Robert Ellis, Mauro Aiello, Hui Ouyang
Publikováno v:
Pharmaceutical Research. 25:1572-1582
To evaluate the sensitivity requirement for LC-MS/MS as an analytical tool to support human microdosing study with sub-pharmacological dose, investigate proportionality of pharmacokinetics from the microdose to therapeutic human equivalent doses in r
Publikováno v:
Xenobiotica. 37:205-220
The characterization of brimonidine metabolites presents some challenges since brimonidine and its metabolites generate few structurally informative fragment ions in the LC-MS/MS spectra. The objective of the current study is to use on-line hydrogen/
Publikováno v:
Clinical Pharmacokinetics. 44:247-261
Ciclosporin is a potent immunomodulator that acts selectively and locally when administered at the ocular surface. 0.05% ciclosporin ophthalmic emulsion has recently been approved by the US FDA for treatment of keratoconjunctivitis sicca (KCS) [dry-e
Autor:
Darius M. Babusis, Scott M. Whitcup, Jennifer Q. Dong, Andrew Acheampong, Devin F. Welty, Diane D.-S. Tang-Liu
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 20:285-292
To determine aqueous humor concentrations of brimonidine given the following ophthalmic formulations in female New Zealand White Rabbits: (1) BAK-preserved brimonidine tartrate 0.20% at a pH of 6.4; (2) BAK-preserved brimonidine tartrate 0.15% at a p
Autor:
Katherine Stern, Randy Epstein, Andrew Acheampong, William C. Stewart, Diane D.-S. Tang-Liu, Brenda Reis, Lance Forstot, David Small, Gregg J. Berdy, Robert Foerster
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 18:411-418
To quantify blood cyclosporin A (CsA) concentrations during treatment with CsA topical ophthalmic emulsions, blood was collected from 128 patients enrolled in a Phase 3, multicenter, double-masked, randomized, parallel-group study of CsA eyedrops for
Autor:
Larry A. Wheeler, James A. Burke, Martha Shackleton, Andrew Acheampong, Diane D.-S. Tang-Liu, Brian A. John
Publikováno v:
Drug Metabolism and Disposition. 30:421-429
The objectives of the study were to evaluate the distribution of brimonidine (alpha2-adrenergic agonist) into anterior and posterior ocular tissues. Single or multiple doses of a 0.2 or 0.5% brimonidine tartrate solution were administered to one or b
Autor:
Jerry A. Shields, Andrew Acheampong, Brian P. Marr, June Chen, Heryberto S. Alvim, Gábor Holló, Carol L. Shields, L. Jay Katz, Sheryl S. Wizov, Parul Ichhpujani, Ralph C. Eagle, Larry A. Wheeler
Publikováno v:
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 28(2)
This study investigated the ocular distribution of bimatoprost, latanoprost, and their acid hydrolysis products in the aqueous humor, cornea, sclera, iris, and ciliary body of patients treated with a single topical dose of 0.03% bimatoprost or 0.005%
Autor:
Scott M. Whitcup, Mayssa Attar, Joan-En Chang-Lin, Devin F. Welty, Andrew Acheampong, Michael R. Robinson, Baruch D. Kuppermann
Publikováno v:
Investigative ophthalmologyvisual science. 52(1)
PURPOSE To determine the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.). METHODS Thirty-four male monkeys (Macaca fascicularis) received bilateral 0.7-mg DEX implants. B